US-based bioprocessing company Repligen Corp has announced a public offering of 2,807,017 shares priced at $42.75 each, to raise $120m.
The company plans to use the funds towards working capital and general corporate requirements, including possible acquisitions, products and technologies.
The divestiture will enable Hill-Rom to enhance its portfolio and focus on key growth platforms.
Chembio Diagnostics Inc plans to issue common stock shares to raise $21.2m.
The US-based point-of-care diagnostic tests developer plans to use the stocks for general corporate purposes.
Glooko Inc has secured $35m through a series C financing round led by Georgian Partners.
Glooko, a US-based patient monitoring platform provider for diabetes, plans to use the funds to expand its market presence.